| Bristol-Myers Squibb SA - Reblozyl 75 mg, Pulver zur Herstellung einer Injektionslösung | | 69592 | | 02 | | Reblozyl 75 mg | | Pulver zur Herstellung einer Injektionslösung | | B03XA06 | | Luspatercept | | 21.05.2026 | | |
| | Composition | | luspaterceptum 75 mg, acidum citricum monohydricum, natrii citras dihydricus, polysorbatum 80, saccharum, acidum hydrochloridum, natrii hydroxidum, pro vitro corresp. natrium max. 1.1 mg. | | Packungsbestandteile | | Dry substance | | | | | | Active Agent | Dose |
|---|
| Luspaterceptum | 75 mg |
| | | | Inactive agents |
|---|
| Citric Acid Monohydrate | | Acidum Hydrochloridum | | Natrii Citras Dihydricus | | Sodium Hydroxide | | Polysorbatum 80 | | Saccharum |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | 75 mg | | | A | | No |
|
|
